证券日报网讯 1月15日，九芝堂发布公告称，公司持股5%以上股东、副董事长、总经理李振国计划自 公告披露15个交易日后3个月内，以集中竞价或大宗交易方式减持不超过16925600股，占剔除回购账户 后总股本2%，用于偿还质押融资。 （文章来源：证券日报） ...

北京商报讯（记者 丁宁）1月15日晚间，九芝堂（000989）发布公告称，公司于近日收到持股5%以上 股东、副董事长、总经理李振国出具的《股份减持计划告知函》，其计划自公告披露之日起15个交易日 后的3个月内以集中竞价或大宗交易方式减持公司股份不超1692.56万股，即不超过公司剔除回购专用账 户股份后的总股本的2%。 公告显示，李振国拟减持原因系用于偿还到期股权质押融资本金及利息。 ...

格隆汇1月15日丨九芝堂（维权）(000989.SZ)公布，持股5%以上股东、副董事长、总经理李振国（持有 本公司股份161,898,371股，占公司总股本的18.91%，占公司剔除回购专用账户股份后的总股本的 19.13%）计划自本公告披露之日起15个交易日后的3个月内以集中竞价或大宗交易方式减持本公司股份 不超过16,925,600股，即不超过公司剔除回购专用账户股份后的总股本的2%。 ...

Group 1 - Luxshare Precision plans to repurchase shares worth between 1 billion to 2 billion RMB, with a maximum repurchase price of 86.96 RMB per share, aimed at implementing employee stock ownership plans or equity incentives [1] - Hanyu Pharmaceutical signed a sales order for GLP-1 raw materials worth 180 million RMB, which accounts for 30.50% of its audited revenue for 2024, potentially positively impacting annual performance [2] - Longpan Technology expects to engage in procurement transactions with CATL worth no more than 7 billion RMB in 2026, as part of a continuous related transaction agreement [3] Group 2 - Hu Silicon Industry reported that the National Integrated Circuit Industry Investment Fund reduced its stake by 32.0113 million shares, representing 0.97% of the total share capital, decreasing its ownership from 16.96% to 15.99% [4] - ST Chengchang completed its stock suspension review after abnormal trading fluctuations, confirming no need for corrections or disclosures, and will resume trading on January 16, 2026 [5] - Luoyang Molybdenum plans to use up to 20 billion RMB of idle funds for wealth management and entrusted financial products, pending shareholder approval [6] Group 3 - Siyuan Electric reported a net profit of 3.163 billion RMB for 2025, a year-on-year increase of 54.35% [7] - Tianji Co. expects a net profit of 70 million to 105 million RMB for 2025, recovering from a loss of 1.361 billion RMB in the previous year [7] - Muyuan Foods anticipates a net profit of 14.7 billion to 15.7 billion RMB for 2025, a decrease of 12.20% to 17.79% compared to the previous year [7] Group 4 - Luoyang Molybdenum forecasts a net profit of 20 billion to 20.8 billion RMB for 2025, representing an increase of 47.80% to 53.71% year-on-year [8] - Kunlun Wanwei expects to report a loss for 2025 [8] - Dalong Real Estate's subsidiary won a 763 million RMB engineering project contract [11]

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2026-001 九芝堂股份有限公司 关于持股 5%以上股东减持股份预披露公告 持股 5%以上股东李振国保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示：九芝堂股份有限公司（以下简称"公司"、"本公司"）持股 5%以上股东、副董事长、总经理李振国（持有本公司股份 161,898,371 股，占 公司总股本的 18.91%，占公司剔除回购专用账户股份后的总股本的 19.13%）计 划自本公告披露之日起 15 个交易日后的 3 个月内以集中竞价或大宗交易方式减 持本公司股份不超过 16,925,600 股，即不超过公司剔除回购专用账户股份后的 总股本的 2%。 公司于近日收到持股 5%以上股东、副董事长、总经理李振国出具的《股份 减持计划告知函》，现将有关情况公告如下： 一、股东的基本情况 1、股东的名称：李振国 2、股东持有股份的总数量、占公司总股本的比例：李振国持有本公司股份 161,898,371 股，占公司总股本的 18.91%，占公 ...

九芝堂公告，持股5%以上股东、副董事长兼总经理李振国持有公司股份1.62亿股，占总股本18.91%， 占剔除回购专用账户股份后总股本19.13%，拟自公告披露之日起15个交易日后的3个月内，以集中竞价 或大宗交易方式减持不超过1692.56万股，不超过公司剔除回购专用账户股份后总股本2%，减持所得拟 用于偿还到期股权质押融资本金及利息。 ...

Core Points - The Ministry of Industry and Information Technology of China has announced the public listing of the 2025 Consumer Brand List, which includes six brands from Hunan Province: Jiu Zhi Tang, Sheng De Xi, Anhua Black Tea, Xiangtan Lotus Seed, Nan County Rice Shrimp, and Qian Jin [1][22]. Group 1: Announcement Details - The announcement is based on the notification from the Ministry of Industry and Information Technology regarding the collection of consumer brands for 2025 [1]. - The public listing period is from January 5, 2026, to January 9, 2026, allowing for public feedback [1]. Group 2: Brand Listings - Six brands from Hunan Province are proposed for inclusion in the 2025 Consumer Brand List: - Jiu Zhi Tang (九芝堂) - Sheng De Xi (圣得西) - Anhua Black Tea (安化黑茶) - Xiangtan Lotus Seed (湘潭湘莲) - Nan County Rice Shrimp (南县稻虾米) - Qian Jin (千金) [1][22].

证券日报网讯12月22日，九芝堂（000989）在互动平台回答投资者提问时表示，公司关注AI技术在公 司业务领域内的发展及应用。 ...

Group 1 - The company disclosed that the net profit attributable to shareholders for the year-to-date period up to the end of the reporting period in the third quarter of 2025 is 151,531,605.68 yuan [2]

Core Viewpoint - The company Ji Xiang Long is leveraging downstream formulation demand to boost sales of upstream raw materials and chemicals, benefiting from the market opportunities created by the expansion of medical insurance coverage [1] Domestic Market - Ji Xiang Long is driving sales of raw materials and chemicals by relying on the demand from the downstream formulation sector [1] - The company is enjoying market dividends from the expansion of medical insurance in the domestic market [1] International Market - Ji Xiang Long primarily exports GLP-1 class drugs (Semaglutide, Tirzepatide) and has obtained DMF registration [1] - The company has not yet received FDA certification as it has not applied for formulation-related approval, thus it is currently exporting in the form of chemicals [1]